Chemotherapeutic Strategies Against Trypanosoma brucei: Drug Targets vs. Drug Targeting

Title: Chemotherapeutic Strategies Against Trypanosoma brucei: Drug Targets vs. Drug Targeting

Volume: 13 Issue: 6

Author(s): A. Luscher, H. P. de Koning and P. Maser

Affiliation:

Keywords: Trypanosoma brucei, sleeping sickness, functional genomics, drug target, chemotherapy, drug resistance

Abstract: Trypanosoma brucei rhodesiense and T. b. gambiense are the causative agents of sleeping sickness, a fatal disease that affects 36 countries in sub-Saharan Africa. Nevertheless, only a handful of clinically useful drugs are available. These drugs suffer from severe side-effects. The situation is further aggravated by the alarming incidence of treatment failures in several sleeping sickness foci, apparently indicating the occurrence of drug-resistant trypanosomes. Because of

Cite this article as:

Luscher A., de Koning P. H. and Maser P., Chemotherapeutic Strategies Against Trypanosoma brucei: Drug Targets vs. Drug Targeting, Current Pharmaceutical Design 2007; 13 (6) . https://dx.doi.org/10.2174/138161207780162809